Average first month weight loss on Wegovy: what the evidence says

Average first-month losses on Wegovy are typically modest: the 0.25 mg starting dose is a tolerability step, and the largest weight changes tend to come at maintenance doses later in treatment.
In the STEP 1 clinical trial (68 weeks, semaglutide 2.4 mg), average weight reduction reached around 15% of body weight — with the bulk of that loss accumulating from month two onwards as doses increased.
Reduced appetite is often the first sign the medicine is working, sometimes weeks before the number on the scales changes noticeably.
Wegovy works alongside a reduced-calorie diet and increased physical activity; the two together consistently produce better outcomes than the medicine alone.

Most people starting Wegovy lose between 1 and 4 kg in their first month, though individual results vary quite a bit. The opening weeks are deliberately a settling-in phase: the 0.25 mg starter dose is designed to help your body adjust, not to deliver immediate dramatic weight loss. By the end of week four, many people notice reduced hunger before the scales shift much at all. Wegovy (semaglutide) is a prescription-only medicine, and how much weight you lose in that first month depends on your dose, your diet, your activity levels, and your own physiology — all things a prescriber considers at consultation.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How first-month results fit into the full Wegovy weight-loss picture

You've just started Wegovy, here's why the first four weeks look the way they do

Picture the scene: you've ordered your first Wegovy pen, it's arrived in plain packaging, and you're expecting the first month to be the biggest. For most people, that's not quite how it works, and understanding why makes the early weeks a lot less frustrating.

Wegovy's dosing pathway begins at 0.25 mg once weekly, a level that exists entirely to reduce the chance of nausea and other gastrointestinal side effects. At that dose, the weight-loss signal is gentle. Most clinical data, including the large STEP 1 trial published in the New England Journal of Medicine, show that the steepest monthly losses happen between months two and six, once patients have titrated up towards the 1.7 mg and 2.4 mg maintenance doses.

If you're curious about what the typical figures look like for Wegovy weight loss after one month, that range is wide for a reason. Someone who was already eating fairly carefully and exercising will see different results than someone making bigger dietary changes. Body weight also fluctuates day to day (fluid shifts, digestion, the timing of a meal) so a single weigh-in at day 28 doesn't tell the full story. If you want a broader view of typical Wegovy results across the full treatment period, the trajectory beyond month one is genuinely more informative.

The thing most patients tell us they noticed first wasn't weight loss at all. It was eating half a plate and feeling satisfied. That appetite shift is the medicine working, even when the scales haven't caught up yet.

What actually drives your first-month result on Wegovy

Average weight loss in the first month of Wegovy is shaped by several overlapping factors, and it's worth being honest about each of them.

Dose is the biggest one. At 0.25 mg, semaglutide's effect on appetite is measurable but limited. The step up to 0.5 mg (typically from week five) tends to produce a more noticeable shift in hunger, and that's often when the scales start moving more meaningfully. The question of how long Wegovy takes to work has a lot to do with where you are in that titration sequence.

Starting weight matters too. Someone with a higher starting BMI tends to see larger absolute losses early on, even if the percentage is similar. Conversely, someone closer to the eligibility threshold may see slower early movement and faster relative change later.

Diet quality and activity level are the variables most firmly in your hands. GLP-1 medicines like semaglutide reduce appetite; they don't rewrite your dietary habits automatically. Adequate protein intake helps preserve muscle during weight loss, which matters for longer-term metabolism. The NHS medicines page for semaglutide explains these lifestyle requirements as part of how the treatment is meant to be used.

Finally, there's biology. Hormonal status, gut microbiome, sleep, stress and medication interactions all influence how quickly the body responds. Two people on identical doses and diets can see genuinely different first-month results, and both can be responding normally.

First month versus the longer picture, and why the comparison matters

Focusing too tightly on week-four weight can lead people to stop treatment that's actually working. The STEP 1 trial, which followed 1,961 adults over 68 weeks, showed that average weight reduction at 2.4 mg reached approximately 15% of starting body weight by the end of the study. Almost none of that happened in month one.

Looking at average weight loss on Wegovy at three months gives a more useful early benchmark, by then, most people have reached or are approaching maintenance dosing, and the cumulative effect is meaningfully larger. Six months in, the difference is starker still. If you're comparing your own progress, a week-by-week view of typical Wegovy weight loss can help calibrate expectations without fixating on any single data point.

One practical note: if you're thinking about starting treatment and you're weighing up timing, the 12pm cut-off for same-day dispatch means a Monday order placed in the morning typically arrives Tuesday, useful to know if you want to start at the beginning of a week rather than mid-holiday.

For people thinking about what Wegovy costs through a private pharmacy, the conversation is worth having alongside a clinical one. A prescriber who understands your full health picture is better placed than any price comparison to tell you whether Wegovy, or one of the other licensed options, is likely to give you the best outcome. If you'd like to explore that with our clinical team, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered prescriber, not a queue or an algorithm.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions